Circadin is Approved in the EU for Treatment of Primary Insomnia in Patients Aged 55 or Over for up to 3 Months

TEL AVIV, Israel, July 5, 2010 – Neurim Pharmaceuticals (www.Neurim.com) confirmed today
that the European Commission (EC) has approved a change in treatment duration
with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the
treatment of primary insomnia in patients who are aged 55 or over.

The approval was based [...]

Finnish Pharmaceutical Innovation: Free Flowing Granulate

PDG Dry Granulation as Valid Alternative to Wet Granulation
HELSINKI, Finland, July 5, 2010 – Standard methods in pharmaceutical production often reach their
technological limits – be it wet granulation, roller compaction or direct
compression. The Finnish company Atacama Labs – www.atacamalabs.com -
with its proprietary pneumatic dry granulation technology extends this limit
successfully and provides free flowing granules [...]